Single‐cell transcriptome profiling reveals blast cell heterogeneity and identifies novel therapeutic target IKZF2 in t(8;21) acute myeloid leukaemia
- 8 August 2025
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 207 (4) , 1309-1322
Abstract
Summary: The t(8;21)(q22;q22) translocation is one of the most recurrent cytogenetic aberrations in acute myeloid leukaemia (AML). While most patients achieve complete remission, approximately 40% of them still relapse. Early identification and elimination of leukaemia clones with relapse potential could improve prognosis for t(8;21) AML patients. Here, through single‐cell RNA sequencing, we characterized the intra‐tumoral heterogeneity of t(8;21) AML and identified haematopoietic stem cell (HSC)‐like subset as the most quiescent and primitive subgroup among all leukaemia cell populations. Further investigations revealed IKZF2 as the master regulator for HSC‐like subset. Notably, IKZF2 was upregulated in t(8;21) AML compared with other AML subtypes and was specifically targeted by AML1‐ETO. Using primary samples and mouse models, we verified the high enrichment of IKZF2 in primitive and quiescent leukaemic cells. Moreover, IKZF2 knockout hindered the accumulation of aberrant stem cells driven by AML1‐ETO and promoted cellular differentiation both in vitro and in vivo. These facilitate a better understanding of the leukaemia cell heterogeneity in t(8;21) AML and unveil IKZF2 as a potential target for improving current treatment strategies.Keywords
Funding Information
- National Natural Science Foundation of China (82000131, 82341213)
- Tianjin Municipal Science and Technology Committee (23JCYBJC01050, 23JCYBJC01060)
- National Key Research and Development Program of China (2021YFC2500300)
This publication has 38 references indexed in Scilit:
- Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myeloid leukemiaAmerican Journal of Hematology, 2023
- Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patientsAmerican Journal of Hematology, 2022
- Integrative analysis of drug response and clinical outcome in acute myeloid leukemiaCancer Cell, 2022
- Definition of a small core transcriptional circuit regulated by AML1-ETOMolecular Cell, 2020
- Expression of RUNX1-ETO Rapidly Alters the Chromatin Landscape and Growth of Early Human Myeloid Precursor CellsCell Reports, 2020
- Gata2 as a Crucial Regulator of Stem Cells in Adult Hematopoiesis and Acute Myeloid LeukemiaStem Cell Reports, 2019
- IKZF2 Drives Leukemia Stem Cell Self-Renewal and Inhibits Myeloid DifferentiationCell Stem Cell, 2019
- Rac1 GTPase Promotes Interaction of Hematopoietic Stem/Progenitor Cell with Niche and Participates in Leukemia Initiation and Maintenance in MouseStem Cells, 2016
- Identification of a Dynamic Core Transcriptional Network in t(8;21) AML that Regulates Differentiation Block and Self-RenewalCell Reports, 2014
- AML1–ETO downregulates the granulocytic differentiation factor C/EBPα in t(8;21) myeloid leukemiaNature Medicine, 2001